Transmitted Drug Resistance in Persons with Acute/Early HIV-1 in San Francisco, 2002-2009

  title={Transmitted Drug Resistance in Persons with Acute/Early HIV-1 in San Francisco, 2002-2009},
  author={Vivek Jain and Teri J. Liegler and Eric Vittinghoff and Wendy Hartogensis and Peter Bacchetti and Lauren A Poole and Lisa Loeb and Christopher D. Pilcher and Robert M. Grant and Steven G. Deeks and Frederick M. Hecht},
  booktitle={PloS one},
BACKGROUND Transmitted HIV-1 drug resistance (TDR) is an ongoing public health problem, representing 10-20% of new HIV infections in many geographic areas. TDR usually arises from two main sources: individuals on antiretroviral therapy (ART) who are failing to achieve virologic suppression, and individuals who acquired TDR and transmit it while still ART-naïve. TDR rates can be impacted when novel antiretroviral medications are introduced that allow for greater virologic suppression of source… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.


Publications citing this paper.
Showing 1-10 of 40 extracted citations

Transmitted drug resistance in patients with acute/recent HIV infection in Brazil.

The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases • 2017

The trend of transmitted drug resistance in newly diagnosed antiretroviral-naive HIV/AIDS patients during 1999-2012 in South Korea.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology • 2016


Publications referenced by this paper.
Showing 1-10 of 28 references

Raltegravir: the first HIV type 1 integrase inhibitor.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2009
View 1 Excerpt

Maraviroc for previously treated patients with R5 HIV-1 infection.

The New England journal of medicine • 2008
View 1 Excerpt

Similar Papers

Loading similar papers…